Immunomodulating Drugs News

News

Infection risk not increased with alemtuzumab : The Lancet Oncology
www.thelancet.com | Feb 13, 2012
Infection risk not increased with alemtuzumab. By - Bryant Furlow

Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com | Feb 10, 2012
< p > Roche Holding Ltd. ( < a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Hldg Ltd Spons' > RHHBY.PK < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 01, 2012 01:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Severin Schwan – Chief Executive

Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
www.prlog.org | Feb 8, 2012
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Laryngeal Cancer Therapeutics Market is Forecast to Show Slow Growth Until 2019 - PR11793534

New Study Helps Predict Which Lung Cancer Drugs are Most Likely to Work - 01/10/2012
www.hopkinsmedicine.org | Jan 27, 2012
Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors like erlotinib—may be

Roches Avastin Fights Early Breast Cancer in 2
www.biospace.com | Jan 26, 2012
Is Avastin back in the fold for breast cancer? The FDA revoked Avastin's approval for treating breast cancer in November, 2011, saying the drug didn't

FDA Notifies Genentech of Violations at Avastin Plant - - BioPharm International
biopharminternational.findpharma.com | Jan 6, 2012
On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company?s South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA

FDA Removes Avastin Breast Cancer Indication - Pharmaceutical Technology
pharmtech.findpharma.com | Dec 16, 2011
The breast cancer indication for Avastin has been revoked after FDA Commissioner Margaret A. Hamburg concluded that the drug has not been shown to be safe and effective for this use.

FDA blow for blockbuster Roche drug - FT.com
www.ft.com | Nov 18, 2011
The US Food and Drug Administration has revoked approval for Roche’s blockbuster drug Avastin to treat breast cancer, dealing a blow to the company and disappointing health groups that have argued the drug has saved lives. Margaret Hamburg, FDA

Roche | Roche reports positive study of Herceptin given by subcutaneous injection | PharmaAsia
www.pharmaasia.com | Oct 18, 2011
Phase 3 study of a quicker route of administration shows comparable results to intravenous Herceptin.

American Society of Retina Specialists Publishes Compounding Pharmacy Information to Promote Safety
www.prweb.com | Oct 4, 2011
Responding to recent incidents of blinding endophthalmitis after injections of Avastin, the American Society of Retina Specialists is publishing safety information for physicians on the compounding pharmacies that prepare the drug for injection into the eye.